FENC — FENNEC PHARMACEUTICALS INC.

—
Nasdaq · Health Care · Biotechnology · CIK 1211583 ·
Last close
$13.45
Market Cap
$474.85M
52W High
$13.85
52W Low
$5.65
ADV30
234,984
Next earnings
2026-11-12
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 19,608,000 18,770,000 4,654,000 4,640,000 83,543,000 48,684,000 34,353,000
Jun 2026 17,874,000 17,153,000 1,737,000 1,973,000 75,753,000 41,249,000 33,311,000
Mar 2026 15,108,000 14,538,000 -119,000 201,000 71,822,000 40,179,000 34,147,000
Dec 2025 13,777,000 12,013,000 -2,580,000 -4,787,000 70,551,000 36,788,000 35,079,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-2,040,000
Investing CF
—
Financing CF
$24,584,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.13
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-227,248,000
Inventory
$2,374,000
Receivables
$23,266,000
ST Investments
—
EBIT TTM
$-2,199,000
Pretax Income TTM
$-3,103,000
Interest Exp TTM
$904,000
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$66,367,000
EBITDA
$3,820,667
Free Cash Flow
$4,055,125
Enterprise Value
$361,561,472
Total Cash
$48,684,000
Total Debt
$0
Shares Out
35,305,117
Trailing EPS
$-0.13
Book Value
$1.40
ROE
9.1%
ROA
3.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 44,642,000 -6,346,000 -9,741,000 70,551,000 35,079,000 35,472,000 -12,473,000
Dec 2024 47,538,000 2,479,000 -436,000 44,946,000 50,818,000 -5,872,000 26,980,000
Dec 2023 21,252,000 -13,058,000 -16,045,000 26,864,000 38,486,000 -11,622,000 -17,143,000
Dec 2022 1,535,000 -22,738,000 -23,714,000 26,939,000 29,508,000 -2,569,000 -18,058,000

TTM Snapshot

Revenues TTM
$59,221,000
NetIncome TTM
$-3,250,000
OpCashFlow TTM
—
Assets (Latest)
$75,753,000
Forward EPS
$1.03

Peers — same industry

TickerNameMarket CapLastDaily %
RGNX REGENXBIO Inc. $474.76M $7.18 —
VALN Valneva SE $508.73M $5.36 —
DNA Ginkgo Bioworks Holdings, Inc. $442.34M $8.20 —
IRLA IRulya Therapeutics Inc. $433.01M $39.94 —
SANA Sana Biotechnology, Inc. $521.36M $1.74 —

News headlines (Yahoo Finance, 1h cache)

Adherex Technologies Q3 Earnings Call Highlights
2026-11-12 17:15 · Yahoo
Fennec Pharma (FENC) Q3 2026 Earnings Call Transcript
2026-11-12 16:31 · Yahoo
Fennec Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 11:03 · Yahoo
Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026
2026-11-06 10:50 · Yahoo
Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
2026-09-17 11:30 · Yahoo
Fennec Pharmaceuticals Inc (FENC) (Q2 2026) Earnings Call Highlights: Record Sales and ...
2026-08-11 21:02 · Yahoo
Fennec Pharmaceuticals surges 8% as Q2 earnings and revenue beat estimates
2026-08-11 14:20 · Yahoo
Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-11 11:01 · Yahoo
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
2026-08-05 11:01 · Yahoo
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-06-22 10:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.